Commercial-stage biopharmaceutical company ADC Therapeutics SA (ADCT) has a clear slate of near-term clinical and operational catalysts that center on ZYNLONTA's development in relapsed or refractory diffuse large B-cell lymphoma and the company's extended financial runway.
The most immediate focus is on additional LOTIS-7 data in the second half of 2025, LOTIS-5 reaching prespecified progression-free survival (PFS) events by year-end, and preparations that position ZYNLONTA for potential advancement across lines of therapy. These events set the stage for data flow and potential regulatory steps through 2026 and beyond.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.